Baseline characteristics

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia · Source last updated 2021-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      4

   2. group Id

      BG001

      value

      2

   3. group Id

      BG002

      value

      6

   4. group Id

      BG003

      value

      0

   5. group Id

      BG004

      value

      0

   6. group Id

      BG005

      value

      0

   7. group Id

      BG006

      value

      0

   8. group Id

      BG007

      value

      12

   units

   Participants

groups

1. description

   Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies

   id

   BG000

   title

   Group I (Dasatinib)

2. description

   Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO

   id

   BG001

   title

   Group II (Sutinib Malate)

3. description

   Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO

   id

   BG002

   title

   Group III (Sorafenib Tosylate)

4. description

   Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO

   id

   BG003

   title

   Group IV (Ponatinib Hydrochloride)

5. description

   Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies

   id

   BG004

   title

   Group V (Pacritinib)

6. description

   Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO

   id

   BG005

   title

   Group VI (Ruxolitinib)

7. description

   Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies

   id

   BG006

   title

   Group VII (Idelalisib)

8. description

   Total of all reporting groups

   id

   BG007

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            69

            upper Limit

            74

            value

            70.5

         2. group Id

            BG001

            lower Limit

            47

            upper Limit

            53

            value

            50

         3. group Id

            BG002

            lower Limit

            31

            upper Limit

            72

            value

            57.5

         4. group Id

            BG007

            lower Limit

            31

            upper Limit

            74

            value

            63

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   Years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         2. group Id

            BG001

            value

            1

         3. group Id

            BG002

            value

            5

         4. group Id

            BG007

            value

            7

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            3

         2. group Id

            BG001

            value

            1

         3. group Id

            BG002

            value

            1

         4. group Id

            BG007

            value

            5

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            3

         2. group Id

            BG001

            value

            2

         3. group Id

            BG002

            value

            4

         4. group Id

            BG007

            value

            9

         title

         White

      2. measurements

         1. group Id

            BG000

            value

            1

         2. group Id

            BG001

            value

            0

         3. group Id

            BG002

            value

            2

         4. group Id

            BG007

            value

            3

         title

         Hispanic or Latino

      title

      Race/Ethnicity

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race/Ethnicity, Customized

   unit Of Measure

   Participants

population Description

Zero patients were enrolled in the Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice